GBC delivers innovative technologies that connect disease detection, cancer monitoring, and laboratory automation, enabling healthcare professionals to make faster and more informed decisions for better patient outcomes.
Find out moreInnovating Diagnostics, Advancing Discovery
R&D is at the heart of GBC’s mission.
From precision diagnostics to next-generation therapeutics and digital healthcare solutions, we are shaping the future of medical innovation.
Our R&D focuses on precision diagnostics (CellBio™, CL i120 CLIA system, AIO M160 molecular diagnostic platform), innovative breakthroughs in P113 antimicrobial peptide therapeutics, and digital healthcare applications powered by AI and big data.
GBC July Revenue Reaches NT$24.63 Million, Up 57.82% YoY
Growing CLIA System Installations to Drive Reagent and Consumables Revenue, Supporting Long-Term Business Growth Hsinchu, Taiwan — August 10, 2026 General Biologicals Corporation (GBC, hereinafter referred to as…
GBC’s ESG Journey: Innovation, Trust & Planet-Conscious Diagnostics
Discover how GBC integrates ESG with low-cost diagnostics and eco-conscious processes—from solvent reduction to ethical governance
Events
We try to participate as many events or shows as much as possible. Try to capture us demoing the newest technologies at the events below.
Join GBC
Unfold Your Future — Join GBC to Innovate Diagnostics and Advance Global Healthcare
Reveal. Better Life.
Since 1984, GBC has pioneered in-vitro diagnostics (IVD) and expanded into next-generation therapeutics and consumer healthcare solutions, delivering innovation trusted in 40+ countries worldwide.